The Thai Food and Drug Administration (Thai FDA), together with a network of pharmacy professional organizations, namely the Pharmacy Council of Thailand, the Hospital Pharmacy Association (Thailand), the Community Pharmacy Association (Thailand), and the Pharmacovigilance Club (Thailand), has signed a Memorandum of Understanding (MOU) to strengthen the system for drug safety surveillance and risk management associated with medicine use. The initiative aims to establish a stronger, more systematic framework with the highest priority placed on public safety.

On 12 February 2026, the Thai Food and Drug Administration (Thai FDA) organized the signing ceremony for the Memorandum of Understanding on “Drug Safety Surveillance and Risk Management Associated with Medicine Use” at TK. Palace & Convention Hotel. The ceremony was held to foster cooperation with professional organizations and pharmacy networks from all sectors in order to develop Thailand’s pharmacovigilance system to meet international standards.

Ms. Supattra Boonserm, Secretary-General of the Food and Drug Administration, stated that drug safety surveillance has been one of the Thai FDA’s key missions, continuously undertaken for more than 40 years. The signing of this MOU therefore marks an important step in strengthening collaboration among both public and private sector networks, including Subdistrict Health Promoting Hospitals and community pharmacies, to jointly advance the surveillance system so that risks and problems associated with medicine use can be identified and managed effectively and in a timely manner. The key areas of cooperation include:

• The development of more effective systems for reporting and monitoring adverse drug reactions;
• The promotion of safe medicine use practices in hospitals, pharmacies, and health service units;
• The strengthening of the capacity of pharmacists and related personnel through enhanced knowledge and expertise;
• The application of digital technology and innovation, such as information systems and artificial intelligence (AI), to support pharmacovigilance activities; and
• Public education to enable people to recognize abnormal symptoms and report them accurately.

In this regard, Ms. Morakot Jaroonwattana, Senior Advisor on Safety, Effectiveness and Use of Health Product, was assigned to represent the Thai FDA at the signing ceremony. Cooperation under this MOU will further strengthen the pharmacovigilance network across hospitals, pharmacies, communities, and the private sector, enabling drug safety surveillance to be carried out in a more systematic manner and reducing risks associated with medicine use.

This will help ensure that Thai people can be confident that they will receive the highest standard of pharmaceutical care. Information on adverse drug reactions will be systematically collected and analyzed in accordance with international standards in order to prevent losses that may arise from adverse reactions to medicines and health products in all dimensions.

******************************************************
Publication date on 13 February 2026